Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

Athens, Greece — December 4, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society…